via timesofmalta.com
Watson Pharmaceuticals has completed its acquisition of the Actavis Group for €4.25 billion to create the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.
The two companies will join forces under the new global name – Actavis – next year.
No comments:
Post a Comment